TNDM vs NVO

For growth investors, Tandem Diabetes Care, Inc.

(TNDM) is the stronger pick with 7. 9% revenue growth year-over-year, versus 6. 4% for Novo Nordisk A/S (NVO). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Tandem Diabetes Care, Inc. (TNDM) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novo Nordisk A/S (NVO) delivered a total return of +39.

0%, compared to -79. 1% for Tandem Diabetes Care, Inc. (TNDM). Over 10 years, the gap is even starker: NVO returned +105. 1% versus TNDM's -75. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tandem Diabetes Care, Inc.

(TNDM) is the lower-risk stock at 1. 45β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 7% more volatile than TNDM relative to the S&P 500. On balance sheet safety, Novo Nordisk A/S (NVO) carries a lower debt/equity ratio of 67% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tandem Diabetes Care, Inc.

(TNDM) is pulling ahead at 7. 9% versus 6. 4% for Novo Nordisk A/S (NVO). On earnings-per-share growth, the picture is similar: Novo Nordisk A/S grew EPS 1. 8% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -20. 2% for Tandem Diabetes Care, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus -7. 7% for TNDM. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TNDM: 75.

4% to $31. 62.

In this comparison, NVO (4.

0% yield) pays a dividend. TNDM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novo Nordisk A/S (NVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (4.

0% yield, +105. 1% 10Y return). Both have compounded well over 10 years (NVO: +105. 1%, TNDM: -75. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TNDM is a small-cap quality compounder stock; NVO is a large-cap deep-value stock. NVO pays a dividend while TNDM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.